Robert F. Kennedy Jr. testified Thursday in Washington at a nomination hearing conducted by the Senate Health, Education, Labor and Pensions Committee. Credit: Senate HELP
Robert F. Kennedy Jr. said he believes in careful use of the GLP-1 agonist anti-obesity drugs to help people coping with morbid obesity or diabetes.
President Donald Trump has nominated Kennedy to be the secretary of the U.S. Department of Health and Human Services, which oversees the U.S. Food and Drug Administration, Medicare and Medicaid and helps enforce the Affordable Care Act commercial health insurance rules.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Allison Bell
Allison Bell, a senior reporter at ThinkAdvisor and BenefitsPRO, previously was an associate editor at National Underwriter Life & Health. She has a bachelor's degree in economics from Washington University in St. Louis and a master's degree in journalism from the Medill School of Journalism at Northwestern University. She can be reached through X at @Think_Allison.
